Lynch interception is the harder vaccine trial, and Nouscom just funded it
An oversubscribed EUR 120M Series D sends an off-the-shelf cancer vaccine toward a prevention trial measured in colonoscopy results from dozens, not thousands, of patients.
Newsletter
Pipeline, markets, policy, and science. Once a week.
Could an Emerging Biotech Asset Be the Key Missing Piece as Big Medtech Bets on Wound Care
Wound care is becoming one of big medtech's next frontiers, and Swedish wound-care leader Mölnlycke just announced a separation into an independent wound-care company. At the center of that landscape sits MediWound (NASDAQ: MDWD).
BioNTech's Cancer Vaccine Missed the Endpoint Pembrolizumab Itself Never Won
AHEAD-MERIT missed its progression-free survival endpoint. In this disease, pembrolizumab itself never won PFS either. The trial now turns to overall survival, the endpoint where this cancer actually rewards immunotherapy.
The First Keytruda Biosimilar Filing Reaches FDA Without a Phase 3 Trial. Can Analytics Carry a $31.7 Billion Molecule?
The FDA has accepted the first publicly announced biosimilar filing for Keytruda, built with no comparative Phase 3 trial. The pathway shortcut, not the molecule, is what reshapes the $31.7 billion franchise.